ArticleNeurochemical research2026
Spinorphin Attenuates Acute Experimental Seizures and Associated Neurochemical Alterations: Possible Involvement of Opioid Receptors.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinorphin, an endogenous enkephalinase inhibitor, enhances physiological opioid signaling by preventing the degradation of endogenous enkephalins, however, its anticonvulsant potential has not previously been investigated. This study evaluated the effects of spinorphin on seizure activity and associated neurochemical alterations in two complementary acute experimental seizure models. The effects of spinorphin on seizure activity were investigated in pentylenetetrazole (PTZ)- and penicillin-induced acute seizure rat models. Behavioral seizure parameters, passive avoidance memory, electrocorticographic activity, cortical and hippocampal glutamate, GABA, c-Fos, calcitonin gene-related peptide (CGRP), inflammatory cytokines, and oxidative stress biomarkers were evaluated. Nalmefene was used to determine the contribution of opioid receptor signaling. Spinorphin significantly attenuated behavioral seizures, reduced cortical epileptiform spike frequency, and improved passive avoidance retention performance. It attenuated PTZ-induced alterations in cortical and hippocampal glutamate and GABA concentrations and reduced tissue levels of c-Fos and CGRP, together with changes in inflammatory and oxidative stress-related biomarkers in both the cortex and hippocampus. These effects were substantially attenuated by nalmefene, suggesting a possible contribution of endogenous opioid signaling, although the incomplete reversal indicates that additional opioid-independent mechanisms may also be involved. Spinorphin attenuates seizure activity and associated biochemical alterations in experimental seizure models. By enhancing the regional availability of endogenous enkephalins rather than directly activating opioid receptors, spinorphin may exert its anticonvulsant effects partly through endogenous opioid signaling, while additional opioid-independent mechanisms may also contribute. These findings provide a basis for further investigation of enkephalinase inhibition in experimental seizure models.
Indexed as
Identifiers
42900439What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.